RxDoctor Payments Data

Warren Chin, MD

Cardiovascular Disease · New York, NYNPI 1700988060

Payments from drug & device makers

$202,823in general payments, 2019–2025

Across 288 payments — averaging $704.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$103K
  • Johnson & Johnson$74K
  • Lilly USA, LLC$19K
  • Pfizer$3K
  • Boston Scientific$1K
  • Medtronic$586
  • plus $3K from 12 others

What the payments were for

  • Consulting fees$3,6752%
  • Speaking & faculty fees$175,46387%
  • Travel & lodging$10,7985%
  • Food & beverage$12,6996%
  • Education$1900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,823 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$176,202
Medicare patients
186
Services billed
1,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban674$540,158
JardianceEmpagliflozin577$525,456
EliquisApixaban334$296,499
KerendiaFinerenone95$90,055
EntrestoSacubitril/Valsartan53$52,708
Diclofenac Epolamine44$32,967
VascepaIcosapent Ethyl82$25,994
MultaqDronedarone Hcl19$18,204
Diclofenac Sodium33$14,946
BrilintaTicagrelor22$12,186
FarxigaDapagliflozin Propanediol14$8,184
Ranolazine ErRanolazine144$6,832
Metoprolol Succinate853$6,516
TradjentaLinagliptin12$6,193
Atorvastatin Calcium817$4,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$73,826$540,158674 claims
Boehringer IngelheimJardiance, Tradjenta$102,561$531,649589 claims
PfizerEliquis$2,776$296,499334 claims
BayerKerendia$374$90,05595 claims
NovartisEntresto$35$52,70853 claims
AstraZenecaBrilinta, Farxiga, Nexium$509$23,40747 claims
Sanofi-aventis U.S. LLCMultaq$212$18,20419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →